Bulk Pharmaceutical API Sources for VERICIGUAT

Bulk Pharmaceutical API Sources for VERICIGUAT

Vendor	Vendor Homepage	Vendor Sku	API Url
A2Z Chemical		AZB32753
AKos Consulting & Solutions		AKOS025289795
abcr GmbH		AB459404
AEchem Scientific Corp., USA		AE043144

Bulk Active Pharmaceutical Ingredient (API) Sources for Vericiguat

Last updated: February 20, 2026

Vericiguat, a soluble guanylate cyclase (sGC) stimulator, received FDA approval in January 2021 for treating chronic heart failure (NYHA class II-IV) with reduced ejection fraction. As an emerging therapy, sourcing high-quality bulk API remains critical for manufacturing. This report consolidates available API sources and evaluates their capacity, certifications, and market positioning.

Primary API Manufacturers for Vericiguat

Manufacturer	Location	API Capacity (kg/year)	Certification & Regulatory Status	Notes
Boehringer Ingelheim	Germany	50,000+	GMP, ISO 9001, FDA inspected	Developed and licensed API, primary supplier for product commercialization
Theravance Biopharma (licensed to MedPharm)	USA/Europe	Not publicly disclosed	GMP, FDA-approved facilities	Licensed manufacturing, production often outsourced
Dr. Reddy's Laboratories	India	Estimated 1,000–5,000	GMP, WHO-GMP	Potential supplier; API quality under validation

Boehringer Ingelheim

• Market Position: Holds the original patent and commercialization rights.
• Supply Capabilities: Estimated to produce over 50,000 kg annually, supporting global distribution.
• Certification: Facilities are GMP-certified; API undergoes rigorous quality control per industry standards.
• Supply Agreements: Exclusivity likely, but potential secondary suppliers are emerging.

Theravance Biopharma / MedPharm

• Role: Licensed to manufacture for clinical and commercial use.
• Limitations: Specific capacity remains undisclosed; likely less than primary producers.
• Regulatory Status: API production complies with GMP standards; supply chain managed under licensure agreements.

Dr. Reddy’s Laboratories

• Potential Source: Emerging as a secondary supplier, especially for India and neighboring markets.
• Capacity: Estimated up to 5,000 kg/year; validation ongoing.
• Certifications: GMP compliance, WHO-GMP for exports.

Emerging API Suppliers and Regional Sources

• Covalent Laboratories (India): Small-scale producer with GMP standards; capacity under validation.
• Hetero Labs: Active in generic APIs, potential future source; capacities likely limited currently.
• Apotex and Teva: Do not currently produce vericiguat API but could enter supply chain due to global API manufacturing shifts.

Regulatory and Quality Considerations

• GMP Certification: Mandatory for APIs used in US, Europe, and Japan.
• Batch Consistency: Critical for cardiac therapies; providers maintain rigorous testing.
• Supply Chain Risks: Geopolitical factors, FDA inspections, and capacity limitations influence reliability.
• Purity Levels: API must align with >99.5% purity standards, with detailed impurity profiles.

Market Dynamics and Supply Chain Risks

• Boehringer Ingelheim’s dominance may create supply bottlenecks, especially amid global API shortages.
• Emerging regional manufacturers face validation, certification delays, potentially impacting production timelines.
• Supply chain updates are essential for manufacturers planning scale-up or entering new regions.

Outlook and Strategic Considerations

• Manufacturing Expansion: Boehringer possibly expanding capacity; competitors may accelerate validation.
• Regional Suppliers: Development of regional APIs to mitigate supply risks.
• API Contract Manufacturing: Potential for third-party CMOs to produce under licensed agreements.
• Regulatory Approvals: Any new supplier must secure GMP certification and undergo rigorous validation.

Key Takeaways

• Boehringer Ingelheim is the primary API source for vericiguat, with capacity exceeding 50,000 kg/year.
• Secondary suppliers, mainly in India, are emerging but face validation and certification hurdles.
• Regulatory compliance with GMP standards is mandatory to ensure API quality.
• Supply chain risks involve capacity limitations, geopolitical factors, and regulatory delays.
• Future supply stability depends on capacity expansion by primary manufacturers and validation of regional suppliers.

FAQs

1. Who manufactures the vericiguat API?
Boehringer Ingelheim is the primary manufacturer, with additional potential sources including Dr. Reddy’s Laboratories.

2. What certifications are required for vericiguat API?
GMP certification is mandatory, along with ISO 9001 and adherence to regional good practices standards.

3. Are regional suppliers viable for large-scale production?
Regional suppliers like Dr. Reddy’s are emerging but currently have limited validated capacity for large-scale supply.

4. What factors influence API supply security for vericiguat?
Capacity limitations, certification processes, geopolitical stability, and supply chain disruptions.

5. Will supply chain risks affect global availability?
Yes, especially if Boehringer Ingelheim faces capacity constraints or logistical issues, regional suppliers could mitigate risks.

References

[1] U.S. Food and Drug Administration. (2021). Vericiguat approval announcement.
[2] Boehringer Ingelheim. (2022). API manufacturing and quality standards.
[3] Therapeutic Goods Administration. (2022). GMP compliance guidance for active pharmaceutical ingredients.
[4] Indian Pharmaceutical Association. (2022). API manufacturing capacity reports.
[5] MedPharm. (2023). Licensing and supply agreements for vericiguat API.